LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Open

Sector Healthcare

16.18 -0.37

Buy Sell

Overview

Share price change

24h

Current

Min

16.1

Max

16.4

Key metrics
By Trading Economics
Income	17M 33M
Sales	36M 242M
EPS	0.2
Profit margin	13.797
Employees	597
EBITDA	12M 33M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+65.01 upside

Dividends
By Dow Jones
Next Earnings	31 Oct 2024

Market Stats
By TradingEconomics
Market Cap	-23M 2.7B
Previous open	16.55
Previous close	16.18

News Sentiment

By Acuity

100%

341 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

15.98 / 16.36 Support & Resistance

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Sept 2024, 23:40 UTC

Hot Stocks

Stocks to Watch: Intel, Netcapital, Microsoft

16 Sept 2024, 22:56 UTC

Acquisitions, Mergers, Takeovers

Xero Bolsters Customer Insights With $70 Million Acquisition of Syft

16 Sept 2024, 19:21 UTC

Acquisitions, Mergers, Takeovers

Vista Equity Partners, Blackstone Close to $8 Billion Buyout Deal for Smartsheet, Reuters Reports

16 Sept 2024, 22:47 UTC

Market Talk

Auckland International Airport's August Traffic Underwhelms -- Market Talk

16 Sept 2024, 22:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 Sept 2024, 22:47 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Sept 2024, 22:41 UTC

Acquisitions, Mergers, Takeovers

Xero Bolsters Customer Insights With $70 Mln Acquisition of Syft

16 Sept 2024, 22:37 UTC

Acquisitions, Mergers, Takeovers

Santos to Own 36.5% of Bayu-Undan Following Sale, Purchase Deed

16 Sept 2024, 22:36 UTC

Acquisitions, Mergers, Takeovers

Santos: Production Sharing Contract for Bayu-Undan to Cease at End-June 2026 or When Output Stops if Earlier

16 Sept 2024, 22:35 UTC

Acquisitions, Mergers, Takeovers

Santos: Bayu-Undan JV Executes Sale, Purchase Deed to Transfer 16% Stake in Upstream Project to Timor GAP

16 Sept 2024, 22:34 UTC

Acquisitions, Mergers, Takeovers

Xero: Syft's More Than 70 Employees Will Transition With Acquisition

16 Sept 2024, 22:31 UTC

Acquisitions, Mergers, Takeovers

Xero: Syft Will Still Be Available as a Standalone Offering

16 Sept 2024, 22:30 UTC

Acquisitions, Mergers, Takeovers

Xero: Syft Is Used in More Than 80 Countries

16 Sept 2024, 22:30 UTC

Acquisitions, Mergers, Takeovers

Xero Expects to Complete Acquisition of Johannesburg-Based Syft in 3Q FY25

16 Sept 2024, 22:29 UTC

Acquisitions, Mergers, Takeovers

Xero to Pay Balance in Earnouts, Restricted Stock Over Three Years

16 Sept 2024, 22:28 UTC

Acquisitions, Mergers, Takeovers

Xero Will Pay US$40 Mln Up Front Including US$10 Mln in Shares

16 Sept 2024, 22:28 UTC

Acquisitions, Mergers, Takeovers

Xero Will Embed Syft to Accelerate Insights, Analytics Offerings

16 Sept 2024, 22:27 UTC

Acquisitions, Mergers, Takeovers

Xero: Syft Services Accountants, Bookkeepers, Small Businesses

16 Sept 2024, 22:27 UTC

Market Talk

Auckland Airport Raises More Equity Than Citi Expected -- Market Talk

16 Sept 2024, 22:26 UTC

Acquisitions, Mergers, Takeovers

Xero: Syft Is a Cloud-Based Reporting, Insights, Analytics Platform

16 Sept 2024, 22:26 UTC

Acquisitions, Mergers, Takeovers

Xero Acquiring Syft Analytics for Up to US$70 Million

16 Sept 2024, 22:08 UTC

Top News

Microsoft Boosts Dividend, Authorizes Up to $60B of Buybacks

16 Sept 2024, 21:17 UTC

Top News

Intel CEO Lays Out New Steps to Cut Costs and Bolster Chip-Making Division -- 2nd Update

16 Sept 2024, 21:16 UTC

Earnings

Tech Growth Is Slowing. These 6 Companies Could Still Shine. -- Barrons.com

16 Sept 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 Sept 2024, 20:46 UTC

Top News

Amazon Tells Workers to Return to Office Five Days a Week -- 2nd Update

16 Sept 2024, 20:34 UTC

Top News

Intel CEO Lays Out New Steps to Cut Costs and Bolster Chip-Making Division -- Update

16 Sept 2024, 20:28 UTC

Top News

Boeing Freezes Hiring, Delays Pay Raises as Strike Worsens Finances -- 2nd Update

16 Sept 2024, 20:19 UTC

Top News

Dow Hits Record as Investors Bet on Bigger Fed Cut -- WSJ

16 Sept 2024, 20:07 UTC

Top News

Intel CEO Lays Out New Steps to Cut Costs and Bolster Chip-Making Division -- WSJ

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

65.01% upside

12 Months Forecast

Average 26.93 USD 65.01%

High 39 USD

Low 17 USD

Based on 18 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

Buy

Hold

Sell

Based on 18 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

15.98 / 16.36Support & Resistance

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

341 / 365 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).